Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
pour les flux de travail chromatographiques et analytiques sensibles nécessitant une interférence de ligne de base minimale.
Store at -20°C Expédition Ice chest + Ice pads. Consultez le COA spécifique au lot pour les spécifications exactes.
SDS, COA, fiche technique et fiche de spécifications disponibles au téléchargement. COA spécifique au lot accessible via la recherche par numéro de lot.
Cité dans 0 publications à comité de lecture couvrant la chromatographie, la synthèse organique et les réactions de couplage croisé.
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 ( Tyk2 ) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a K i value of 0.086 nM for Tyk2 JH2 and an IC 50 value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis
In Vitro
Tyk2-IN-5 inhibits Jak1-3 with IC 50 values of >2 μM and displays the Jak1-3 dependent cellular activities of >12.5 μM (IC 50 values). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Tyk2-IN-5 (5, 10 mg/kg; p.o.; twice daily for 20 days) shows highly efficacious in a rat adjuvant arthritis model . Tyk2-IN-5 (1, 10 mg/kg; p.o.; single) inhibits IL-12/IL-18 induced IFNγ production in a dose-dependent manner . Tyk2-IN-5 (10 mg/kg; p.o.; single) shows a high oral exposure and bioavailability (114%) in rat . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Lewis male rats (rat adjuvant arthritis model) . Dosage: 5, 10 mg/kg Administration: Oral administration; twice daily for 20 days Result: Demonstrated full efficacy to prevent the rats′ paw from swelling. Animal Model: Lewis male rats (IL-12/IL-18-induced) . Dosage: 1, 10 mg/kg Administration: Oral administration; single Result: Inhibited IL-12/IL-18 induced IFNγ production by 45% and 77% at doses of 1 and 10 mg/kg, respectively. Animal Model: Lewis male rats, mouse . Dosage: 10 mg/kg Administration: Oral administration; single Result: 1.19 Pharmacokinetic Parameters of Tyk2-IN-5 in mouse and rat . PO (10 mg/kg) mouse rat C max (μM) 15 9.4 AUC 0-24 (μM•h) 19 57 CL (mL/min/kg) 16 7.8 F (%) 86 114
Form:Solid
IC50& Target:Tyk2 JH2 0.086 nM (Ki) IFNα 25 nM (IC 50 )
Document complet couvrant les dangers, la manipulation, le stockage et la conformité réglementaire.
<<<<<<< HEAD Télécharger la SDS → ======= Télécharger la SDS → >>>>>>> release248-p3Données qualité spécifiques au lot. Saisissez votre numéro de lot pour récupérer le COA exact.
Rechercher le COA →Résumé de référence rapide des spécifications et applications du produit.
Voir la fiche technique →Attributs de qualité complets et critères d'acceptation pour cette qualité.
Voir la fiche de spécifications →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Classe | Carboxylic acids and derivatives |
| Subclass | Carboxylic acid derivatives |
| Intermediate Tree Nodes | Carboxylic acid amides |
| Direct Parent | 2-heteroaryl carboxamides |
| Alternative Parents | Secondary alkylarylamines Pyridinones Aminopyridazines Aminopyridines and derivatives Carbonylimidazoles Dihydropyridines N-substituted imidazoles Imidolactams Heteroaromatic compounds Secondary carboxylic acid amides Amino acids and derivatives Lactams Azacyclic compounds Organic oxides Alkyl fluorides Organofluorides Organooxygen compounds Organopnictogen compounds Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | 2-heteroaryl carboxamide - Pyridinone - Aminopyridazine - Aminopyridine - Secondary aliphatic/aromatic amine - Imidazole-4-carbonyl group - Dihydropyridine - N-substituted imidazole - Pyridazine - Pyridine - Imidolactam - Hydropyridine - Azole - Imidazole - Heteroaromatic compound - Secondary carboxylic acid amide - Lactam - Amino acid or derivatives - Azacycle - Organoheterocyclic compound - Secondary amine - Organooxygen compound - Amine - Alkyl halide - Alkyl fluoride - Hydrocarbon derivative - Organic oxide - Organopnictogen compound - Organic oxygen compound - Organic nitrogen compound - Organonitrogen compound - Organohalogen compound - Organofluoride - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group. |
| External Descriptors | Not available |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Solubilité | DMSO : 43.33 mg/mL (99.74 mM; Need ultrasonic) |
|---|---|
| Poids moléculaire | 434.400 g/mol |
| XLogP3 | 1.900 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 434.162 Da |
| Monoisotopic Mass | 434.162 Da |
| Topological Polar Surface Area | 117.000 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 807.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |